Skip to main content

Advertisement

SpringerLink
Log in

Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Background

To assess the impact of location versus number of extra-pulmonary metastatic sites (EPMS) on survival in stage IV non-small cell lung cancer (NSCLC).

Methods and materials

Retrospective analysis was conducted on patients diagnosed during 1999–2013 with stage IV, M1b (AJCC 7th edition) NSCLC using the large, institutional Glans-Look Database, which contains patient demographic, clinical, pathological, treatment, and outcome information. We assessed the impact of location and number of EPMS and identified correlates of overall survival using the Kaplan–Meier method and Cox regression.

Results

We identified a total of 2065 NSCLC patients with EPMS. Median age was 67 (IQR 58–75) years, 52% were men, and 78% were current or former smokers. 60% had one EPMS, and 40% had two or more EPMS. Among those with only one EPMS, most frequent organ involvement included bone (40%), brain (32%), and liver (13%). Median overall survival (mOS) was worst in those with liver metastasis and best in those with adrenal metastasis (2.0 vs. 5.2 months, p = 0.015). However, outcomes based on site of organ involvement were not significantly different in multivariable analysis. Compared to patients with one EPMS, individuals with two or more EPMS experienced worse outcomes (mOS ≤ 2.9 vs. 3.9 months, p < 0.001), and were associated with worse prognosis in Cox regression analysis (HR 1.5, 95% CI 1.3–1.7, p < 0.001).

Conclusions

Number rather than location of EPMS is a prognostic factor in patients with stage IV M1b NSCLC. This information is relevant for accurate prognostication, stratification of participants in future clinical trials, and timely and appropriate advanced care planning.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Canadian Cancer Statistics 2017. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Toronto: Canadian Cancer Society; 2017. http://www.cancer.ca/Canadian-CancerStatistics-2017-EN.pdf. Accessed 28 Aug 2017.

  2. Niu F, Zhou Q, Yang J, et al. Distribution and prognosis of uncommon metastases from non-small cell lung cancer. BMC Cancer. 2016;16:149. https://doi.org/10.1186/s12885-016-2169-5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Riihimaki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84. https://doi.org/10.1016/j.lungcan.2014.07.020.

    Article  PubMed  CAS  Google Scholar 

  4. Kawano D, Takeo S, Katusura M, Tsukamoto S, Masuyama E, Nakaji Y. Surgical treatment of stage IV non-small cell lung cancer. Int Cardiovasc Thorac Surg. 2012;14(2):167–70. https://doi.org/10.1093/icvts/ivr036.

    Article  Google Scholar 

  5. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl 5):e341S–358S. https://doi.org/10.1378/chest.12-236.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Ramalingam SB, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer. Recent advanced and future directions. Oncologist. 2008;13(suppl 1):5–13. https://doi.org/10.1634/theoncologist.13-S1-5.

    Article  PubMed  CAS  Google Scholar 

  7. Non-small cell. lung cancer survival rates, by stage. American Cancer Society. http://cancer.org/cancer/lungcancer-non-smallcell/detailedhuide/non-small-cell-lung-cancer-survival-rates. Published May 16, 2016. Accessed 28 Aug 2017.

  8. Dias M, Coutinho D, Linhas R, et al. Non-small lung cancer: are M1a and M1b the same Stage? Eur Respir J. 2015; 46(suppl 59): PA4288. https://doi.org/10.1183/13993003.congress-2015.PA4288.

    Article  Google Scholar 

  9. Tamura T, Kurishsima K, Nakazawa K, et al. Specific organ metastases and survival in mNSCLC. Mol Clin Oncol. 2015; 3(1):217 https://doi.org/10.3892/mco.2014.410.

    Article  PubMed  Google Scholar 

  10. Hendriks LE, Derks JL, Postmus PE, et al. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: results from a population-based study. Eur J Cancer. 2015;51:2534–44.

    Article  PubMed  CAS  Google Scholar 

  11. R: A language and environment for statistical computing [computer program]. Version 3.3.0. Vienna, Austria. R Foundation for Statistical Computing, R Core Team; 2016. https://www.R-project.org.

  12. Ko JJ, Tudor R, Li H, et al. Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003–2006 with 2010–2011. Curr Oncol. 2017. https://doi.org/10.3747/co.24.3691.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Pikin O, Ryabov A, Glushko V, et al. Does surgery have real benefit in resectable oligometastatic NSCLC? J Thorac Oncol. 2017;12(1):s779.

    Article  Google Scholar 

  14. Newton PK, Mason J, Bethel K, et al. Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Res. 2013;73(9):2760–9. https://doi.org/10.1158/0008-5472.CAN-12-4488.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Bates J, Milano M. Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. J Thorac Dis. 2017;9(7):1903–10. http://jtd.amegroups.com/article/view/14548.

  16. Eberhardt WEE, Mitchell A, Crowley, et al. The IASLC lung cancer staging project: proposals for the revision of the m descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515–22. https://doi.org/10.1097/JTO/000000000000673.

    Article  PubMed  Google Scholar 

  17. Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of tumor micro-environment in lung cancer metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40:558–66. https://doi.org/10.1016/j.ctrv.2013.10.001.

    Article  PubMed  CAS  Google Scholar 

  18. Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. Front Oncol. 2014. https://doi.org/10.3389/fonc.2014.00248.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Chen YM, Fang YT, Lai CH, et al. A survival scoring system for non-small cell lung cancer patients with de novo bone metastases. PLoS ONE. 2016;11(12):e0167923. https://doi.org/10.1371/journal.pone.0167923.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Joss RA, Burki K, Dalwuen P, et al. Combination chemotherapy with mitomycin, vindestine and cisplatin or non-small cell lung cancer. Association of antitumor activity with initial tumour burden and treatment center. Cancer. 1990;65:2426–34.

    Article  PubMed  CAS  Google Scholar 

  21. Oh Y, Taylor S, Bekele BM, et al. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009;115:2930–8.

    Article  PubMed  Google Scholar 

  22. Alexander BM, Othus M, Caglar HB, et al. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:1381–7.

    Article  PubMed  Google Scholar 

  23. Park JH, Kim TM, Keam B, et al. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive getfitinib. Clin Lung Cancer. 2013;14(4):383–9. https://doi.org/10.1016/j.cllc.2012.10.007.

    Article  PubMed  CAS  Google Scholar 

  24. Goldie JH, Colman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 1984;44:3643–53.

    PubMed  CAS  Google Scholar 

  25. Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PloS Comput Biol. 2009;5:e1000557.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Chang YP, Chen YM, Lai CH, et al. The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer. PloS ONE. 2017;12(6):e0178676. https://doi.org/10.1371/journal.pone.0178676.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010;12(11):1193–9. https://doi.org/10.1093/neuonc/noq076.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809–18. https://doi.org/10.1016/S0140-6736(08)61758-4.

    Article  PubMed  CAS  Google Scholar 

  29. Ishii H, Azuma K, Yamada K, Kinoshita T, Imamura Y, Hoshino T. Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib. Oncol Lett. 2014;8:2699–704. https://doi.org/10.3892/ol.2014.2548.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Lee DS, Kang JH, Lee CG, et al. Predicting survival in patients with advanced non-squamous non-small cell lung cancer: validating the extent of metastasis. Cancer Res Treat. 2013;45(2):85–102. https://doi.org/10.4143/crt.2013.45.2.95.

    Article  Google Scholar 

  31. Iyengar P, Lau S, Donington JS, Suh RD. Local therapy for limited metastatic non-small cell lung cancer: what are the options and is there a benefit? Presentation at: ASCO Annual Meeting; June 6, 2016; Chicago.

  32. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small cell lung cancer. N Engl J Med. 2010;363(8):733–42. https://doi.org/10.1056/NEJMoa1000678.

    Article  PubMed  CAS  Google Scholar 

  33. Pirl WF, Greer JA, Traeger L, et al. Depression and survival in metastatic non-small cell lung cancer: effects of early palliative care. J Clin Oncol. 2012;30(12):1310–5. https://doi.org/10.1200/jco.2011.28.3166.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. Ca Cancer J Clin. 2017;67:93–9. https://doi.org/10.3322/caac.21388.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Cumming School of Medicine, University of Calgary, 1331 29th St NW, Calgary, AB, T2N 4N2, Canada

    Amanda Jane Williams Gibson, Haocheng Li, Adrijana D’Silva, Roxana A. Tudor, Anifat A. Elegbede, Shannon Mary Otsuka, D. Gwyn Bebb & Winson Y. Cheung

  2. Tom Baker Cancer Centre, Alberta Health Services, 1331 29th St NW, Calgary, AB, T2N 4N2, Canada

    D. Gwyn Bebb & Winson Y. Cheung

Authors
  1. Amanda Jane Williams Gibson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haocheng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adrijana D’Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roxana A. Tudor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anifat A. Elegbede
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shannon Mary Otsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Gwyn Bebb
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Winson Y. Cheung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Winson Y. Cheung.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gibson, A.J.W., Li, H., D’Silva, A. et al. Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer. Med Oncol 35, 117 (2018). https://doi.org/10.1007/s12032-018-1182-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-018-1182-8

Keywords

Search

Navigation